Drug intelligence / Profile preview

troplasminogen alfa

Development stage: Phase 2
Lead developer: Vernalis
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous

Overview

Troplasminogen alfa (code name V10153) is a recombinant plasminogen activator stimulator developed for the potential treatment of thrombotic disorders and cardiovascular diseases. It acts as a novel fibrinolytic agent by stimulating plasminogen activation, thereby promoting clot dissolution. The drug was developed by Vernalis and has undergone phase II clinical trials for acute myocardial infarction and acute ischemic stroke[1][3][5]. Its mechanism involves enhancing endogenous fibrinolysis to restore blood flow in occluded vessels.

Other names: troplasminogen alfa

Targets

PLG (Plasminogen)

Beyond the preview

Go deeper on troplasminogen alfa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on troplasminogen alfa.

Explore the full profile